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Background: Epidemiological studies demonstrate that foetal growth restriction and low birth weight affect
long-term health. Derangements in tissue-specific epigenetic programming of foetal and placental tissues are a
suggested underlying mechanism of which DNA methylation is best understood. DNA methylation has been
mostly investigated in DNA from white blood cells. To improve baseline understanding of tissue-specific DNA
methylation, we examined variation in DNA methylation profiles of the imprinted foetal growth genes IGF2 and H19
in three different tissues from the same newborn obtained at the same time.
Findings: We obtained DNA from umbilical cord blood mononuclear cells (MNC; CD34+ and CD34–, n = 6), foetal
side of the placenta (n = 5) and umbilical cord Wharton jelly (n = 5). DNA methylation of the IGF2 differentially
methylated region (DMR) and H19 DMR was measured using quantitative mass spectrometry. Analysis of variance
testing showed no statistical difference between total mean methylation of CD34+ and CD34– MNC. Further
comparisons were made with the pooled total MNC fraction. Mean IGF2 DMR methylation of Wharton jelly
was 1.3 times higher (P = 0.001) than mean methylation of the pooled MNC. Placental mean methylation was
0.8 times lower (P <0.001) and Wharton jelly 0.9 times lower (P <0.001) than the pooled MNC of H19 DMR.
Conclusion: The total MNC fraction is a rather homogeneous cell population for methylation studies of imprinted
genes in umbilical cord blood white blood cells, but may not always reflect the methylation levels of IGF2 and H19
in other organs.
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Background
The prenatal period is critical for adverse pregnancy out-
come and chronic diseases in adulthood [1]. Epigenetic
programming of foetal and placental tissues is a sug-
gested underlying mechanism, of which DNA methyla-
tion is best understood [2,3].
DNA methylation profiles are tissue specific in somatic
and germline tissues [2,4,5]. This is important in the
tissue-specific regulation of cellular differentiation and
lineage maintenance [6-8]. However, human methylation
profiles are mostly performed in DNA from an easily* Correspondence: r.steegers@erasmusmc.nl
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reproduction in any medium, provided the oraccessible, heterogeneous white blood cell population.
DNA methylation studies often select imprinted loci as
candidate genes, because DNA methylation levels at these
loci were assumed to be comparable in different tissues.
Recent literature, however, has questioned this assumption
[2,9,10]. The imprinted IGF2–H19 gene complex, involved
in placental, embryonic and foetal growth and develop-
ment, has been described extensively in this context. Both
genes are located near each other and are reciprocally
imprinted [11]. Studies have demonstrated in mice that
placental Igf2 knockout results in foetal growth restriction,
whereas H19 silencing leads to foetal overgrowth [12,13].
In human, the phenotype related to the silencing of IGF2
is Silver Russell syndrome and H19 silencing is related to
Beckwith Wiedemann syndrome [9].
From this background, we aimed to improve the base-
line understanding of tissue-specific variation in DNA
methylation profiles of the imprinted genes IGF2 andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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nuclear cells (MNC), placental tissue and Wharton jelly de-
rived from the umbilical cord. The rationale for selecting
these tissues is that they are easily accessible, MNC consist
of a rather homogeneous population of white blood cells,
and placental and umbilical cord tissues are involved in
foetal programming and development. Moreover, morpho-
logical abnormalities in these tissues are related to preg-
nancy complications, in which epigenetic derangements
might be involved [14-17]. To examine a possible methyla-
tion difference between MNC subpopulations, CD34+ and
CD34– fractions were also analysed separately.Methods
Maternal, pregnancy and child characteristics
In this study we analysed samples of six pregnancies.
Median maternal age was 30.5 years (range: 23.8 to 37.3)
and median parity was 0.5 (0 to 2). All pregnancies
were uncomplicated, except one gestational hypertension
(peak blood pressure: 140/90 mmHg). Deliveries were at
term and spontaneously, median birth weight was 3,303 g
(2,795 to 3,975). Two out of six newborns were male. Sam-
ples were collected after written informed consent was
obtained before delivery at the Erasmus MC, University
Medical Centre Rotterdam, the Netherlands. Ethical ap-
proval was given by the Erasmus MC, University Medical
Centre Research Ethics Board (MEC-2004-227).Sample collection
Immediately after delivery of the newborn with the pla-
centa still in situ, umbilical cord blood (n = 6) was col-
lected in cord blood collection bags containing 21 ml
anticoagulant citrate phosphate dextrose solution. The
placenta (n = 5) and umbilical cord (n = 5) were col-
lected within 10 minutes after delivery of the placenta.
Samples of 0.5 cm3 were taken from the foetal side of
the placental villi at four different sites in a 3 cm radius
around the umbilical cord insertion, after carefully re-
moving the membranes and 2 mm of the top placental
layer. Wharton jelly from the umbilical cord was isolated
in pieces of 0.5 cm2 avoiding the umbilical cord vessels.
Tissues were frozen immediately in liquid nitrogen and
stored at −80°C until DNA extraction. All samples were
collected by two researchers.Table 1 Characteristics of primers per gene
Forward primer Reverse primer
IGF2 DMR aggaagagagTGGATAG
GAGATTGAGGAGAAA
cagtaatacgactcactatagggagaag
AAACCCCAACAAAAACCACT
H19 DMR aggaagagagGGGTTTGG
GAGAGTTTGTGAGGT
cagtaatacg actcactata gggagaa
ATACCTACTACTCCCTACCTACC
NCBI build: 37. Tags in lowercase. Chr chromosome, DMR differentially methylated rBlood cell separation
Umbilical cord blood was processed within 48 hours
after collection. Using Ficoll gradient centrifugation, the
MNC fraction was obtained and washed. CD34+ MNC
were isolated from this pool by magnetic-activated cell
separation using a Direct CD34 Progenitor Cell Isolation
Kit (130-046-702; Miltenyi Biotec, Bergisch Gladbach,
Germany) according to the manufacturer’s protocols.
The remaining cells were collected and further analysed
as CD34– MNC.DNA extraction
Placental and Wharton jelly tissues were ground on liquid
nitrogen and lysed overnight at 55°C using cell lysis buffer.
Subsequently, genomic DNA was extracted from all tissues
using the Gentra Puregene Tissue Kit (Qiagen, Hilden,
Germany), following the manufacturer’s instructions.DNA methylation measurement
The amplicons for IGF2 and H19 have been described
previously [18]. The amplicon for IGF2 is located in
the IGF2 differentially methylated region (DMR), up-
stream of exon 1 of IGF2. For H19, the amplicon partly
overlaps a CpG island, which is part of the H19 DMR,
upstream of exon 1 of H19. Table 1 shows the location,
length and primers of the amplicons. Firstly, the am-
plicons were tested on a standard curve constructed
from DNA with low and high methylation (EpigenDx,
Worcester, MA, USA) at stages of 10% methylation dif-
ference. Only amplicons with a good distribution of the
methylation percentages were used for measurements of
the samples.
Isolated genomic DNA (500 ng) was treated with so-
dium bisulphite for 16 hours using the EZ-96 DNA
methylation kit (Shallow; Zymo Research, Irvine, CA,
USA). This was followed by PCR amplification, reverse
transcription, fragmentation and analysis on a mass
spectrometer (Sequenom, Inc., San Diego, CA, USA).
This generated mass signal patterns that were translated
into quantitative DNA methylation levels per CpG site
by Mass ARRAY EpiTYPER Analyzer software (v1.0,
build1.0.6.88; Sequenom, Inc.) [19]. Fragments containing
one or more CpG sites were called CpG units. Measure-
ments were performed in triplicate on DNA from the
same bisulphite-treatment batch on different PCR plates.Base pair length Position CpG sites (n)
gct 338 Chr. 11: 2,169,458
to 2,169,796
7
ggct
AAC
413 Chr. 11: 2,019,371
to 2,019,784
20
egion.
Table 2 Absolute methylation levels of the different tissues per gene and per CpG site
CD34+ MNC CD34– MNC Pooled MNC Placental tissue Wharton jelly
IGF2 DMR (total) 0.55 (0.14) 0.50 (0.13) 0.50 (0.13) 0.54 (0.16) 0.65 (0.13)†*
IGF2 DMR CpG 3 0.59 (0.05) 0.52 (0.02) 0.52 (0.02) 0.59 (0.07) 0.66 (0.07)†
IGF2 DMR CpG 4 0.64 (0.18) 0.59 (0.18) 0.59 (0.18) 0.58 (0.25) 0.77 (0.11)
IGF2 DMR CpG 6.7 0.43 (0.06) 0.39 (0.03) 0.39 (0.03) 0.44 (0.03) 0.52 (0.06)†
H19 DMR (total) 0.30 (0.02) 0.31 (0.02) 0.31 (0.02) 0.25 (0.02)† 0.28 (0.03)†*
H19 DMR CpG 2 0.28 (0.01) 0.29 (0.01) 0.29 (0.01) 0.26 (0.01) 0.27 (0.04)
H19 DMR CpG 9.10 0.31 (0.01) 0.31 (0.02) 0.31 (0.02) 0.26 (0.03) 0.30 (0.04)
H19 DMR CpG 12 0.28 (0.02) 0.29 (0.01) 0.29 (0.01) 0.23 (0.02)† 0.26 (0.02)†
H19 DMR CpG 13 0.30 (0.01) 0.31 (0.01) 0.31 (0.01) 0.24 (0.01)† 0.28 (0.03)
H19 DMR CpG 17 0.34 (0.02) 0.35 (0.01) 0.35 (0.01) 0.25 (0.03)† 0.31 (0.03)*
Data presented as mean (standard deviation). Analysis of variance testing between the different tissue groups. Bonferroni correction was applied to all P values to
adjust for multiple comparisons. DMR differentially methylated region; MNC mononuclear cells.
†P <0.05 versus pooled MNC (pairwise comparisons).
*P <0.05 versus placenta (pairwise comparisons).
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50%, 75% and high methylation was included.
Data cleaning
During quality control, CpG units with a very low mass
or very high mass or CpG units with overlapping RNA
fragments were excluded from further analysis. Two out
of three of the replicate measurements per CpG unit
had to be successful, and the standard deviation of the
duplicates or triplicates had to be ≤0.10 to be included
in the statistical analysis. CpG units with interference of
SNPs were also excluded (dbSNP134). After quality con-
trol, 3 CpG units for IGF2 DMR and 9 CpG units for
H19 DMR remained for further analysis.
Statistical analysis
Possible batch effects were ruled out by comparing means
of the standards per bisulphite plate and PCR plate with
analysis of variance testing. To analyse total methylation
per gene and per individual CpG unit between tissues,Figure 1 Mean absolute DNA methylation levels per CpG site for the
(coloured dots) of all individuals ±2 standard deviations (coloured bars) sho
(A) IGF2 DMR and (B) H19 DMR. DMR, differentially methylated region; MNCanalysis of variance testing was used, followed by pairwise
comparisons. We adjusted the total methylation per gene
for the number of CpG units.
We checked and confirmed the normal distribution
by visual inspection of the residuals. Several individual
CpG sites showed significant differences in variance of
DNA methylation. We excluded one patient and 4
CpGs from further testing for the H19 DMR to deal
with this variation. Analysis of variance was finally
performed on 3 CpG units of IGF2 DMR and 5 CpG
units of H19 DMR.
Firstly, we analysed CD34+ and CD34– MNC sepa-
rately, followed by a weighted pooled total MNC fraction
after these two fractions appeared not statistically dif-
ferently methylated. The original CD34+ and CD34– data
were pooled in a 1:100 distribution, comparable with the
biological appearance of CD34+ cells in an umbilical
cord blood MNC fraction. Bonferroni correction was
applied to correct for multiple comparisons. All tests
were performed using means of the data in triplicate.IGF2 DMR and H19 DMR. Error plots of mean methylation levels
wn for each CpG unit for each of the three tissues separately for
, mononuclear cells.
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(SPSS, Inc., Chicago, IL, USA).
Results
The mean methylation of CpG sites of the IGF2 DMR
and the H19 DMR are depicted in Table 2. IGF2 DMR
and H19 DMR methylation of CD34+ and CD34– MNC
were not statistically different, neither the total mean
methylation per amplicon nor the individual CpG units.
Further comparisons were therefore made with the
weighted pooled total MNC fraction as a reference
group. The mean IGF2 DMR methylation of Wharton
jelly (P = 0.001) was statistically significantly higher than
the mean methylation of MNC. This was similar in two
out of the three individual IGF2 DMR CpG units.
The mean H19 DMR methylation of both the placenta
(P <0.001) and Wharton jelly (P <0.001) was statistically
significantly lower than of MNC. This was similar in one
out of five individual H19 DMR CpG units and only ap-
plied to placenta in two other CpG units. Wharton jelly
was statistically significantly higher methylated than pla-
centa in the IGF2 DMR (P = 0.032) and H19 DMR
(P <0.001), as well as one individual H19 CpG unit
(Table 2 and Figure 1).
Conclusion
This study provides a basic understanding of tissue-
specific variation in DNA methylation of two imprinted
genes in easily accessible tissues. The total MNC fraction
of CD34+ and CD34– appears rather homogeneous for
DNA methylation analysis of these genes in umbilical
cord blood. The observed between-tissue methylation
differences seem to be small and could be explained ei-
ther by consistently higher and lower methylation or by
differences in sensitivity of tissues to environmental ex-
posures, foetal and maternal factors. This needs further
investigation in a larger sample size and therefore only
careful conclusions should be drawn from these data.
Umbilical cord blood MNC are thus useful and easily ac-
cessible to study associations between epigenetic program-
ming and pregnancy course and outcome, but do not
always exactly reflect the methylation levels of other organs.
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